SCHEMBL496566

SCHEMBL496566

N[C@H](Cc1cc(F)ccc1F)[C@@H](O)CN1CCc2ccccc2C1

nearest known ligand 0.51

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PRMT5 O14744 16/20 0.51
KDM4E B2RXH2 1/20 0.47
MAPK1 P28482 1/20 0.47
HTT P42858 1/20 0.47
NPSR1 Q6W5P4 1/20 0.47
WDR77 Q9BQA1 12/20 0.45
CARM1 Q86X55 1/20 0.44
HTR1A P08908 1/20 0.42
DRD2 P14416 1/20 0.42
HTR2A P28223 1/20 0.42
SLC6A4 P31645 1/20 0.42
HTR7 P34969 1/20 0.42
DRD3 P35462 1/20 0.42
HTR2B P41595 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL496305 0.99 PRMT5 (0.50) PRMT5KDM4EMAPK1HTTNPSR1
SCHEMBL495544 0.81 DPP4 (0.48) KDM4E
SCHEMBL4754668 0.81 DPP4 (0.48) KDM4E
SCHEMBL4754678 0.81 DPP4 (0.48) KDM4E
Hydrochloric Acid SCHEMBL496687 0.80 DPP4 (0.47) KDM4E
SCHEMBL4748304 0.80 PRMT5 (0.58) PRMT5KDM4EMAPK1HTTNPSR1
SCHEMBL496381 0.78 PRMT5 (0.56) PRMT5HTTWDR77CARM1
SCHEMBL495715 0.78 SCN9A (0.49) PRMT5KDM4EMAPK1HTTNPSR1
SCHEMBL495717 0.78 SCN9A (0.49) PRMT5KDM4EMAPK1HTTNPSR1
Hydrochloric Acid SCHEMBL495605 0.77 PRMT5 (0.55) PRMT5HTTWDR77CARM1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1910317-B1 1-AMINO LINKED COMPOUNDS LILLY CO ELI (US) 2013-07-03 EP disclosed
US-8106090-B2 Antidiabetic agents; prevent of non-insulin dependent diabetes ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
US-8106090-B2 Antidiabetic agents; prevent of non-insulin dependent diabetes ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
US-8106090-B2 Antidiabetic agents; prevent of non-insulin dependent diabetes ELI LILLY AND COMPANY (US) 2012-01-31 US disclosed
US-20080207735-A1 1-Amino Linked Compounds ELI LILLY AND COMPANY 2008-08-28 US disclosed
US-20080207735-A1 1-Amino Linked Compounds ELI LILLY AND COMPANY 2008-08-28 US disclosed
US-20080207735-A1 1-Amino Linked Compounds ELI LILLY AND COMPANY 2008-08-28 US disclosed
WO-2007015805-A1 1-AMINO LINKED COMPOUNDS ELI LILLY AND COMPANY (US) 2007-02-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080207735-A1 1-Amino Linked Compounds DPP4, DPP3, DPP9 PRMT5 1142/4885KDM4E 2377/4885MAPK1 1856/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.